|54.98||+2.45||+4.66%||Vol 632.49K||1Y Perf 166.65%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||35.83||Analyst Rating||Strong Buy 1.08|
|Potential %||-34.83||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||97.03||Earnings Rating||—|
|Market Cap||2.68B||Earnings Date||13th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2021||-0.69||-39.85||-5 675.36|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.56|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||567.03K|
|Avg. Monthly Volume||896.33K|
|Avg. Quarterly Volume||581.50K|
Arcellx Inc. (NASDAQ: ACLX) stock closed at 54.98 per share at the end of the most recent trading day (a 4.66% change compared to the prior day closing price) with a volume of 632.49K shares and market capitalization of 2.68B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. Arcellx Inc. CEO is .
The one-year performance of Arcellx Inc. stock is 166.65%, while year-to-date (YTD) performance is 77.47%. ACLX stock has a five-year performance of %. Its 52-week range is between 18.7 and 56.09, which gives ACLX stock a 52-week price range ratio of 97.03%
Arcellx Inc. currently has a PE ratio of -8.20, a price-to-book (PB) ratio of 6.23, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -70.65%, a ROC of -111.26% and a ROE of -257.16%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Arcellx Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Arcellx Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arcellx Inc. is Strong Buy (1.08), with a target price of $35.83, which is -34.83% compared to the current price. The earnings rating for Arcellx Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcellx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcellx Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 68.42, ATR14 : 3.18, CCI20 : 77.52, Chaikin Money Flow : 0.17, MACD : 4.04, Money Flow Index : 65.68, ROC : 20.84, RSI : 69.29, STOCH (14,3) : 91.18, STOCH RSI : 0.83, UO : 61.35, Williams %R : -8.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcellx Inc. in the last 12-months were: Christopher Heery (Option Excercise at a value of $654 080), Christopher Heery (Sold 70 863 shares of value $2 456 596 ), Rami Elghandour (Option Excercise at a value of $0), Rami Elghandour (Sold 31 442 shares of value $967 423 )
Thu, 02 Nov 2023 22:40 GMT Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), AnaptysBio (ANAB)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.